



34ª Reunião Annual da SBQ  
*Química para um mundo melhor*



Sociedade Brasileira de Química

26.05.2011 - Sessão Temática

## FÁRMACOS E MEDICAMENTOS

Ronaldo A. Pili - UNICAMP

Adriano Lisboa Monteiro – UFRGS

# O paradigma de Fischer & Ehrlich na Química Medicinal moderna



**Eliezer J. Barreiro**  
Professor Titular – UFRJ

Química  
e  
Medicinal

Laboratório de Avaliação e Síntese de Substâncias Bioativas

LASSBio<sup>®</sup>

Instituto Nacional de Ciência e Tecnologia em Fármacos e Medicamentos

INCT-INOVAR





O quê podemos considerar como conhecimento em Química Medicinal ?

## O Químico Medicinal

O **Químico Medicinal** utiliza conhecimento híbrido da **Química** e da **Biologia**, integrando equipe interdisciplinar, *na busca de novos fármacos*, em atividade interativa contínua de otimização de inúmeras variáveis moleculares dos novos compostos-protótipos que inventa!



# Cronologia histórica da Química Medicinal





**Emil Fischer**

1852-1919

**1902**



**1908**



**Paul Ehrlich**

1854-1915



# O paradigma de Fischer-Ehrlich

**LOCK & KEY**  
CONCEPT

[http://nobelprize.org/nobel\\_prizes/chemistry/laureates/1902/fischer-lecture.pdf](http://nobelprize.org/nobel_prizes/chemistry/laureates/1902/fischer-lecture.pdf)



**Planejamento racional**



**One-molecule, one-target paradigm**

**Biorreceptor**

**macromolécula**

**baseado no sítio de reconhecimento**

**Química Medicinal**

**Fármaco**

**micromolécula**

**baseado no ligante / análogo-ativo**

**P. Ehrlich, *Chemotherapeutics: scientific principles, methods and results. Lancet* 1913, 2, 445**



Os fármacos atuam em alvos terapêuticos...

... os **biorreceptores**




Estima-se que hoje sejam **483**  
os **biorreceptores** envolvidos na  
resposta terapêutica de todos  
os fármacos contemporâneos.



# A maioria dos biorreceptores dos fármacos contemporâneos são proteínas ...



Química  
Medicinal




A.L. Hopkins & C.R. Groom, The Drugable genome, *Nature Rev. Drug Discov.* **2002**, 1, 727






“...The unprecedented increase in human life expectancy, which has almost doubled in a hundred years, is mainly due to drugs and to those who discovered them.”

Química  
Medicinal




Alfred Burger

em “The practice of medicinal chemistry”, Wiley, 1970, p. 4.



propranolol  
1964



James W. Black

1988



J.W. Black & J. S. Stephenson, *Lancet* **1962**, 280, 311.

M.J.A. Walker, The major impacts of James Black's drug discoveries on medicine and pharmacology, *Trends in Pharmacological Sciences* **2011**, 32, 183.





# A STUDY OF THE ADRENOTROPIC RECEPTORS

RAYMOND P. AHLQUIST

*From the Department of Pharmacology, University of Georgia School of Medicine*

AUGUSTA, GEORGIA


Received for publication May 10, 1948.



**T**HE adrenotropic receptors are those hypothetical structures or systems located in, on or near the muscle or gland cells affected by epinephrine. The concept of a receptive mechanism was introduced by Langley (1, 2) to explain the action of curare on skeletal muscle. Dale was probably the first to make significant use of the receptor concept in connection with the sympathetic nervous system. In his classical paper (3) on the sympatholytic action of the ergot alkaloids, he recognized that what he called the sympathetic myoneural junction could also be called 'the receptive mechanism for adrenaline'; and he used this mechanism to explain the fact that the ergot alkaloids prevented only the motor (excitatory) actions of epinephrine and had no effect on the inhibitory actions of epinephrine or on the excitatory actions of barium or pituitrin.



1988 - James W. Black






“... when it comes to drug discovery  
you're not trying to make  
complicated molecules,  
but make molecules that  
will be effective.”

Química  
Medicinal



Barry J. Price, Glaxo, 1989



cimetidina  
1975



C. Robin Ganellin  
JW Black  
GJ Durant  
JC Emmett  
SK&F  
**1975**

J.W. Black, G.J. Durant, J.C. Emmett, C.R. Ganellin, *Nature* 1974, 248, 65


C.R. Ganellin, Cimetidine, *em Chronicles of Drug Discovery*, JS Bindra & D Lednicer Eds., Wiley, Nova Iorque, Vol. 1, p. 1-38.




“Considering the vast size of chemical space to be explored,\* it is not surprising that experience and intuition are the characteristics that distinguish the most successful medicinal chemists.”

A. L. Hopkins & A. Polinsky  
Knowledge and Intelligence in Drug Design,  
*Annu. Rept. Med. Chem.* 2006, 41, 425.

Química  
Medicinal




\* Número de possíveis moléculas com propriedades farmacêuticas =  $ca. 10^{60}$



Joseph P. Vacca  
Merck

**1996**

J. P. Vacca *et al.*, *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 4096; B. D. Dorsey *et al.*, *J. Med. Chem.* **1994**, *37*, 3443; J. H. Lin, D. Ostovic, J. P. Vacca, The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development, em *Integration of Pharmaceutical Discovery and Development, Case Histories*, R.T. Borchardt, R.M. Freidinger, T.K. Sawyer & P.L. Smith Eds, Plenum Press, Nova Iorque, 1998, p. 233-255.



“... success (*in drug discovery*) depends on the proper integration of new promising technologies with the experience and strategies of classical medicinal chemistry.”

Química  
Medicinal




Hugo Kubinyi, 2003

H. Kubinyi, *Nature Rev. Drug Discov.* **2003**, 2, 667



# Química Medicinal



Validação clínica / Validação terapêutica



O composto-protótipo é um autêntico candidato a nova entidade química, *i.e.* um novo fármaco, portanto é muito mais valioso do que um mero ligante (>>hit) !





Universidade Federal do Rio de Janeiro



# O Químico Medicinal




- **Lock-key concept: Emil Fischer**



- **One-target-one-ligand approach**

One-ligand/one-disease


Paul Ehrlich & magic bullets



- **Ligands for two targets**

Dual, binary, dimeric, bivalent, mixed ligands

TXS-TPant; 5-HT<sub>1A</sub>Rant-SSRI; COX-LOX;



Freyne, 1987

Monge, 2001




LASSBio-272

Teixeira, 1998

# Symbiotic lead-candidates

*compound able to be effective in **two** different targets, both relevant to disease, belonging to distinct biochemical pathway;*



## The symbiotic-lead candidate design

E.J. Barreiro & C.A.M. Fraga, New insights for multifactorial disease therapy: the challenge of the symbiotic drugs, *Current Drug Therapy* 2008, 3, 1.

Química  
e Medicinal


2005

**INCT-INO FAR**

[www.inct-inofar.ccs.ufrj.br](http://www.inct-inofar.ccs.ufrj.br)



Novo candidato a fármaco anti-asmático



**Os efeitos sutis da estrutura na atividade farmacológica!**

M. S. C. Amador et al., Protective Effects of LASSBio-468 phosphoramidate prodrug on lung function and remodeling in TNF- $\alpha$  murine model of chronic asthma, *Br J Pharmacol* 2006, 149, 233-243

M. S. C. Amador et al., Protective Effects of LASSBio-468 phosphoramidate prodrug on lung function and remodeling in TNF- $\alpha$  murine model of chronic asthma, *Br J Pharmacol* 2006, 149, 233-243



synbiotic prototypes, *Bioorg. Med. Chem.* 2009, 17, 74





## The Methylation Effect in Medicinal Chemistry

E. J. Barreiro, A. E. Kümmerle and C. A. M. Fraga



**15 Da**


CH/ $\pi$  interactions from the methyl group of timine. Conformational changes, wich could be involved on maintenance of life.


*The stereoelectronic effects of the methyl group have great importance on biological events and are widely used by the Medicinal Chemistries in the development of new drugs.*

The inductive eletronic effect of the methyl group is the responsible for the subtype receptors selectivity (H<sub>2</sub>x H<sub>1</sub>) on cimetidine

### Stereoelectronic Properties

MW = 15,03  
MR = 5,65 cm<sup>3</sup>/mol  
 $\pi$  hansch = 0,56  
 $\sigma$  hammett = -0,17





cimetidina  
1975



C. Robin Ganellin  
JW Black  
GJ Durant  
JC Emmett  
SK&F  
**1975**

J.W. Black, G.J. Durant, J.C. Emmett, C.R. Ganellin, *Nature* 1974, 248, 65

C.R. Ganellin, Cimetidine, *em Chronicles of Drug Discovery*, JS Bindra & D Lednicer Eds., Wiley, Nova Iorque, Vol. 1, p. 1-38.



- Contato →
- Cursos →
- Disciplinas →
- Editais de Seleção →
- Informações Gerais →
- Orientadores e Linhas de Pesquisa →

**Programa de Pós Graduação em Farmacologia e Química Medicinal**  
**2006**

29 de abril de 2008

“Medicinal chemistry is a discipline at the intersection of chemistry and pharmacology involved with discovery of new drugs.”


**Interface Química-Biologia em Química Medicinal**

Farmacologia  
Química Medicinal

MAIS  
Interdisciplinaridade

Programa de Pós-Graduação em

armacologia & Química medicinal



**Único programa de pós-graduação (M/D) com este perfil na América Latina (2011) !**



INSCRIÇÕES

01 de setembro

a

30 de novembro  
de

2011

150 vagas



LASSBio®  
Laboratório de Pesquisa e Síntese de Substâncias Bioativas

[www.farmacia.ufrj.br/lassbio](http://www.farmacia.ufrj.br/lassbio)

C O N V I T E





*Muito Obrigado pela  
presença e atenção.*